<DOC>
	<DOCNO>NCT02544763</DOCNO>
	<brief_summary>This trial consist 2 part : double-blinded phase open-label extension phase . The blinded phase describe record . Participants receive 1 2 dos GWP42003-P match placebo . The primary clinical hypothesis difference GWP42003-P placebo effect seizure frequency .</brief_summary>
	<brief_title>A Randomized Controlled Trial Cannabidiol ( GWP42003-P , CBD ) Seizures Tuberous Sclerosis Complex ( GWPCARE6 )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Key Participant welldocumented history epilepsy , compatible electroencephalogram ( EEG ) clinical history . Participant clinical diagnosis Tuberous Sclerosis Complex ( TSC ) accord criterion agree 2012 International TSC Consensus Conference . All medication intervention epilepsy ( include ketogenic diet neurostimulation device epilepsy ) must stable 1 month prior screen participant willing maintain stable regimen throughout trial . Key Participant history pseudoseizures . Participant clinically significant unstable medical condition epilepsy . Participant illness 4 week prior screen randomization , epilepsy , opinion investigator could affect seizure frequency . Participant undergone general anesthetic 4 week prior screen randomization . Participant undergone surgery epilepsy 6 month prior screen . Participant consider epilepsy surgery procedure involve general anesthesia . Participant take felbamate , take less 1 year prior screen . Participant take oral mTOR inhibitor . Participant know suspected hypersensitivity cannabinoids excipients Investigational Medicinal Product ( IMP ) , sesame oil . Participant active suicidal plan/intent past 6 month , history suicide attempt last 2 year , 1 lifetime suicide attempt . Participant CSSRS grade 4 5 screening . Participant currently use past use recreational medicinal cannabis , cannabinoidbased medication , within 3 month prior screen unwilling abstain duration study . Participant tumor growth , opinion Investigator , could affect primary endpoint . Participant significantly impair hepatic function screen randomization visit Participant receive IMP within 12 week prior screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>